Author(s):
Safitri, Heri Wijaya, Rusdiati Helmidanora
Email(s):
heriwijaya.luc@gmail.com
DOI:
10.52711/2231-5691.2026.00019 
Address:
Safitri, Heri Wijaya*, Rusdiati Helmidanora
Faculty of Pharmacy, Sekolah Tinggi Ilmu Kesehatan Samarinda, Air Hitam, Samarinda 75124, East Kalimantan, Indonesia.
*Corresponding Author
Published In:
Volume - 16,
Issue - 2,
Year - 2026
ABSTRACT:
The increasing cost of health care requires an analysis that considers the aspect of economic efficiency in treatment. Gastritis is one of the diseases with a high prevalence that requires clinically effective and economically efficient therapy. This study aims to determine the minimum cost between the use of lansoprazole and omeprazole in hospitalized patients with gastritis at Dirgahayu Hospital Samarinda using the cost minimization analysis method. This study uses a pharmacoeconomic approach to identify alternative therapies with lower costs without reducing clinical effectiveness. In the pharmacoeconomic approach, the cost minimization analysis method is used to compare the costs of two health interventions that have equivalent clinical effectiveness. This study uses a quantitative study design with retrospective data collection and data are analyzed using cost minimization analysis to determine the minimum cost between the costs of lansoprazole and omeprazole treatment. Statistical methods are used to evaluate significant differences between groups. The sampling technique used is purposive sampling based on predetermined inclusion and exclusion criteria. The analysis includes fixed costs and variable costs. The results showed that patients with omeprazole therapy had the lowest cost with CMA per patient of IDR 2,495,987 compared to lansoprazole therapy with CMA per patient of IDR. 2,512,812 which had a relatively higher cost, however, there was no significant difference in the minimum cost between patients using omeprazole and patients using lansoprazole. The use of omeprazole and lansoprazole as gastritis therapy needs to be evaluated not only from a clinical perspective, but also in terms of cost efficiency. Through a cost minimization analysis approach, this study emphasizes the importance of choosing a therapy that provides clinical benefits equivalent to more economical expenditure in hospital health care practices.
Cite this article:
Safitri, Heri Wijaya, Rusdiati Helmidanora. Cost Minimization Analysis of Lansoprazole and Omeprazole in Inpatient Gastritis patients at Dirgahayu Hospital Samarinda. Asian Journal of Pharmaceutical Research. 2026; 16(2):128-4. doi: 10.52711/2231-5691.2026.00019
Cite(Electronic):
Safitri, Heri Wijaya, Rusdiati Helmidanora. Cost Minimization Analysis of Lansoprazole and Omeprazole in Inpatient Gastritis patients at Dirgahayu Hospital Samarinda. Asian Journal of Pharmaceutical Research. 2026; 16(2):128-4. doi: 10.52711/2231-5691.2026.00019 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2026-16-2-4
REFERENCES:
1. Puspasari H. Wardani K. Rizky M. Analisis Biaya Pengobatan Pasien Diagnosa Demam Tifoid di Instalasi Rawat Inap RSUD Dr Soedarso Pontianak Tahun 2018. Jurnal Farmasi Dan Ilmu Kefarmasian. 2023; 7(1).
2. Kementerian Kesehatan Republik Indonesia. Pedoman Penerapan Kajian Farmakoekonomi. Kementerian Kesehatan Republik Indonesia. 2013.
3. Bayti C. Gambaran Pola Hidup Mahasiswa Perantauan Terhadap Kejadian Gastritis Di Universitas Samudra. Jurnal Ilmiah Pendidikan Biologi, Jurnal Ilmiah Pendidikan Biologi. 2021; 13(1): 43–47.
4. Nirmalarumsari C. Tandipasang F. Faktor Resiko Kejadian Gastritis Di Wilayah Kerja Puskesmas Bantilang Tahun 2019. Journal of Ners and Midwifery. 2020; 7(2): 196–202.
5. Irianty H. Hayati R. Suryanto D. Kejadian Gastritis Berdasarkan Aspek Promosi Kesehatan dan Pola Makan. Window of Health Jurnal Kesehatan. 2020; 3(3): 251-258.
6. Styoningsih R. Amananti W. M P. S. Presepan Penggunaan Obat Gastritis Pada Pasien Rawat Jalan di Klinik Syifa Ar- Rachmy Slawi, Politeknik Harapan Bersama Tegal. 2020; 6(1): 3.
7. Vilas Sonagre, Piyush Lulay, Meka Lingam, Srinivas Arutla, Sachi Patel, Meghana Kulkarni. Current Advances in Technology of Proton Pump Inhibitor Formulations. Research J. Pharm. and Tech. 2012; 5(1): 20-26, https://rjptonline.org/search.aspx?key=Current%20Advances%20in%20Technology%20of%20Proton%20Pump%20Inhibitor%20Formulations
8. Habibilah H. Y. Hakim R. Airlangga H. Systematic Literature Review: Perbandingan Efektivitas Penggunaan Omeprazole dengan Lansoprazole sebagai Bagian Dari Rejimen Terapi Helycobacter pylori. Journal of Community Medicine. 2021; 9(1): 2.
9. Wulandari C. Farmakoekonomi Di Era Dunia Kesehatan Saat Ini: Tantangan dan Peluang. Falkutas Matematika Dan Ilmu Pengetahuan Alam Universitas Pakuan. 2024; 3(1): 2.
10. Dharmagadda S. Naik GJ. Muragundi MP. Ligade V. Nagaraju PS. Kulkarni M. Cost-Minimization Analysis of Medication Used in the Management of End-stage Renal Disease. Indian Journal of Pharmaceutical Education and Research. 2023; 57(1).
11. V. Sathish Kumar, SK. Abdul Rahaman, T. Deepika, CH. Manoj kumar. Prevalence and General Medications Utilization, Cost Minimization Analysis of Drugs in Hepatic Impairment Patients at A Tertiary Care Hospital. Research J. Pharm. and Tech. 2019; 12(10): 4873-4878. https://www.doi.org/10.5958/0974-360X.2019.00844.8
12. Restyana A. Farmakoekonomi (1nd ed.). Future Science. 2024.
13. Lorensia A. Buku Ajar Farmakoekonomi Menghadapi Tingginya Lonjakan Biaya Pengobatan yang Mengancam Kestabilan Perekonomian (1st ed.), M-Brothers Indonesia. 2020.
14. Rascati K. L. Essentials of Pharmacoeconomics (3nd ed.). Wolters Kluwer. 2020.
15. Setiawan D. Endarti D. Suswantika A. A. Buku Farmakoekonomi Modeling (1nd ed.). UM Purwokerto Press. Purwokerto 2017.
16. Rai M. Farmakoekonomi dalam Pelayanan Kesehatan. Universitas Sant Gadge Baba Amravati. 2018; 1(12): 465 – 472.
17. Arnold R. J. G. Pharmacoeconomics From Theory to Practic (3nd ed.), CRC Press. 2021.
18. Wroblewski LE. Richard MPJ. Wilson K. T. Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk. Clinical Microbiology Reviews. 2016; 23(4): 713–739.
19. Rohani. Futriani ES. Tridiyawati F. Putri D.M. Hubungan Pola Makan dengan Kejadian Gastritis Pada Mahasiswa Tingkat II Di Sekolah Tinggi Ilmu Kesehatan Abdi Nusantara Jakarta Tahun 2018. Jurnal Antara Keperawatan. 2022; 3(2): 448-452.
20. Syiffatulhaya E. N. Wardhana M, F. Andrifianie F. Sari, R. D. P. Faktor Penyebab Kejadian Gastritis. Agromedicine. 2023; 10(1): 65–69.
21. Ahmed A. ElHofy A. Masaod A. Hendy A. Elsayed H. Abdou M. Reda M. Rafiq M. Elkhadry Z. Peptic Ulcer Diseases. Damanhour University. 2024; DOI:10.13140/RG.2.2.25644.27529
22. Muris D. I. Herman H. Hasrawati A. Profil Presepan Penggunaan Obat Gastritis Pada Pasien Rawat Jalan Di RSUD Batara Guru Belopa Periode Januarai – Maret 2023. Pharmaceutical Science Journal. 2024; 2(2).
23. Suresh Kolli, K. Vijayasri, P.N. Murthy. Formulation and invitro evaluation of delayed release multiple unit pellets of Lansoprazole in capsules. Research Journal of Pharmacy and Technology. 2021; 14(5): 2625-0. https://www.doi.org/10.52711/0974-360X.2021.00462
24. Veeranagoud Biradar, Jeevan Matada Basavarajaiah, Myat Thu Thu Win, Leneena Gudugunta, Suresh KV, Sathiyavathi Mahendra Kumar, Neeraja Turagam, Lavanya Priya. In vitro Evaluation of Gastro Retentive Drug Delivery System of Lansoprazole. Research J. Pharm. and Tech 2019; 12(8): 3649-3653. https://www.doi.org/10.5958/0974-360X.2019.00622.X
25. Tanpure R. R., Kolhe M. H., Shinde G. S., Bhor R. J. A Review on Simultaneous Estimation of combination of Omeprazole and Domperidone in Bulk and Tablet by RP-HPLC Method. Research Journal of Pharmacy and Technology. 2024; 17(5): 2409-2. https://doi.org/10.52711/0974-360X.2024.00377
26. Yeomans ND, Tulassay Z, Juhasz L, Rácz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998; 338(11): 719–26. doi:10.1056/NEJM199803123381103
27. Lorenzoni L. Marino A. Understanding variations in hospital length of stay and cost: Results of a pilot project. OECD Health Working Paper No. 94, Paris. 2017; https://dx.doi.org/10.1787/ae3a5ce9-en.
28. Kasi A. O. Kalesaran C. F. A., Ratag. T. B. Hubungan Kebiasan Makan dengan Kejadian Gastritis di Wilayah Kerja Puskesmas Tateli Kabupaten Minahasa. Jurnal Kesmas. 2019; 8: 7.
29. Wieczorek K.Targonskaya A. Maslowski K. Reproductive Hormones and Female Mental Wellbeing. MDPI. 2023; 3: 432–444, https://doi.org/10.3390/ women3030033.
30. Yunanda F. T.Wahyurianto Y. Retna T. Triana W. Gambaran Faktor Penyebab Terjadinya Gastritis di Desa Tlogowaru Wilayah Kerja Puskesmas Temandang Kabupaten Tuban. Jurnal Multidisiplin Indonesia. 2023; 2(8): 1742–1757.
31. Meriyanti. Elliya R. Triyoso. Stres psikologis dan gejala kekambuhan gastritis kronis pada lansia: Studi cross-sectional. Holistik Jurnal Kesehatan. 2022; 16(3): 215 – 222
32. Srebro J. Brniak W. Mendyk A. Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives. Pharmaceutics. 2023; 14. https://doi.org/ 10.3390/pharmaceutics14102043.
33. Sari NP. Retno KE. Sari M. Wadhana AM. Analisis Efektivitas Biaya Omeprazole dan Lansoprazole pada Pasien Gastritis di Instalasi Rawat Inap Rumah Sakit Pertamina Balikpapan. Prosiding Seminar SAFANA. Universitas Mulia. 2024.
34. Rosyidah AK. Primananda ZA. Sabaan W. Sukoharjanti TB. Analisis Efektivitas Biaya Perawatan Terapi Gastritis pada Pasien Unit Rawat Inap di RSI Sunan Kudus Tahun 2018–2020. Indonesia Jurnal Farmasi. 2022; 7(1): 52 – 62.
35. Prasad M. Farland MV. Thacke. PH. Puri R. Lawate SP. Efficacy and Safety of Omeprazole for the Treatment of Acid Peptic Disorders : A Systematic Review and Meta-Analysis. International Journal of Clinical Practice. 2024; https://doi.org/10.1155/2024/9990554.
36. Ramadan E. Pandapotan FA. Suwantika AA. Cost-Effectivieness Analysis of Gastritis Treatment For Inpatient Patients In Sumedang Regency Hospital. Faculty of Pharmacy Padjadjaran University. 2022; 21(3).
37. Kwon YH. So Many Choices, So Little Value: Potential Savings from Selecting Cost Efective Proton Pump Inhibitors. PharmacoEconomics. 2025; 9: 461–469. https://doi.org/10.1007/s41669-025-00563-5.